Merck, AGX806, 2019-nCoV Nucleocapsid Recombinant Antigen,full length (Ag-6)

General description
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the virus strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus closely related to the SARS virus. A SARS-CoV-2 nucleocapsid antigen can be used to support the detection of SARS-CoV-2 (COVID-19, 2019-nCoV).
This E. coli recombinant protein 2019-nCoV Nucleocapsid Recombinant Antigen,full length (Ag-6), Cat. No. AGX806 is tested for use in Lateral Flow Assay.
Biochem/physiol Actions
SARS-CoV-2
Physical form
Purified
Column Purification
Purified protein in 10 mM Phosphate buffer, 150 mM NaCl with no preservatives, pH 7.4.

Preparation Note
Stable for 1 year at -20°C from date of receipt. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.